Colin Quinn, MD

Spencer BE, Irwin DJ, Van Deerlin VM, Suh E, Lee EB, Elman L, Quinn CC, Amado D, Baer M, Grossman M, Wolk DA, McMillan CT. Polygenic associations with clinical and neuropathological trait heterogeneity across TDP-43 proteinopathies , PLoS One, 20: 2025,e0338398

Spencer BE, Xie SX, Ohm DT, Elman L, Quinn CC, Amado DA, Baer M, Lee EB, Van Deerlin VM, Dratch L, Massimo L, Irwin DJ, McMillan CT. Cumulative incidence of motor and cognitive features in the amyotrophic lateral sclerosis-frontotemporal degeneration spectrum , Brain Commun, 7: 2025,fcaf405

Schiava M, Parkhurst Y, Henderson M, Polvikoski T, Valtcheva MV, Nishino I, Inoue M, Nishimori Y, Saito Y, Stojkovic T, Villar-Quiles RN, Romero NB, Evangelista T, Malfatti E, Souvannanorath S, Pegoraro E, Riguzzi P, Monforte M, Bortolani S, Torchia E, Sabatelli M, Tasca G, Straub V, Marini-Bettolo C, Guglieri M, Cetin H, Gelpi E, Klotz S, De Bleecker JL, Alonso-Jimenez A, Baets J, De Ridder W, De Jonghe P, Claeys KG, Thal DR, Bevilacqua JA, Luo S, Zhu W, Lin J, Papadimas G, Papadopoulos C, Zamba-Papanicolaou E, Xirou S, Pal E, Rodolico C, Kostera-Pruszczyk A, Kierdaszuk B, Kaminska A, Muelas N, Vilchez JJ, Domínguez-González C, Hernandez-Lain A, Alonso-Perez J, Nedkova-Hristova V, Aledo C, Oldfors A, Badrising UA, Kushlaf H, Lloyd TE, Ikenaga C, Alfano LN, Quinn CC, Walk D, Vorgerd M, Weihl C, Olivé M, Diaz-Manera J; VCP International Study Group. Muscle Biopsy Findings in Valosin-Containing Protein Multisystem Proteinopathy , Neurol Genet, 11: 2025,e200265

Fournier CN, Quinn CC. The Amyotrophic Lateral Sclerosis Multidisciplinary Clinic: Broke but Not Broken , Neurology, 104: 2025,e210189

Austin MA, Supple GE, Carrell S, Quinn C, Elman L, Nazarian S. Atrial Fibrillation and Flutter in a Contemporary Cohort of Patients With Myotonic Muscular Dystrophy , JACC Clin Electrophysiol: 2025

Fournier CN, Levine M, Simmons K, García-Santibáñez RC, Rowland A, Quinn CC, Ho DT, Bedlack RS, Glass JD. ALS Motor Observational Telemedicine Objective Rasch-Built Assessment: A Quantitative Scale for the Era of Teleneurology , Neurol Clin Pract: 2025

Kishnani PS, Byrne BJ, Claeys KG, Díaz-Manera J, Dimachkie MM, Kushlaf H, Mozaffar T, Roberts M, Schoser B, Hummel N, Kopiec A, Holdbrook F, Shohet S, Toscano A; PROPEL Study Group. Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease , J Patient Rep Outcomes, 8: 2024,132

Morganroth J, Bardakjian TM, Dratch L, Quinn CC, Elman LB. Enhancing Clinical Infrastructure for the Delivery of Intrathecal and Genetic Therapies: A Qalsody (Tofersen) Model for Patients With SOD1-ALS , Neurol Clin Pract: 2024

Benatar M, Hansen T, Rom D, Geist MA, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg LH, Morales RJ, Chio A, Andersen PM, Pradat PF, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal NA, Meyer T, Hanna MG, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph AC, Neuwirth C, Nations S, Shefner JM, Turner MR, Wuu J, Bennett R, Dang H, Sundgreen C; ORARIALS-01 trial team. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial , Lancet Neurol: 2024

Quinn C, Baer M, Amado DA, Kelley M, Elman L. A single ALS center experience with clinical use of sodium phenylbutyrate-taurursodiol , Muscle Nerve: 2024